KR930007439A - 방출 조절형 제약 조성물 - Google Patents
방출 조절형 제약 조성물 Download PDFInfo
- Publication number
- KR930007439A KR930007439A KR1019920020034A KR920020034A KR930007439A KR 930007439 A KR930007439 A KR 930007439A KR 1019920020034 A KR1019920020034 A KR 1019920020034A KR 920020034 A KR920020034 A KR 920020034A KR 930007439 A KR930007439 A KR 930007439A
- Authority
- KR
- South Korea
- Prior art keywords
- pharmaceutical composition
- methyl
- active ingredient
- layer
- hydrophilic polymer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
본 발명은 (a)1종 이상의 충전제와 pH에 독립적인 친수성 중합체로 이루어진 외층; 및 (b) 각각 활성 성분을 함유하는 하나 이상의 내층으로 이루어지고, 여기서, 외층은 투여후 용해 및 침식의 조합에 의하여 점진적으로 제거되고, 내층 또는 내층들은 용해 및 침식의, 분해의 조합에 의하여 점진적으로 제거되거나, 일단 노출된 후 신속히 붕해되는 방출 조절형 제약 조성물 및 그의 제조방법에 관한 것이다. 특히 본 발명은 H2-길항제 또는 세로토닌 작용제 또는 길항제의 조절된 방출을 위한 제약 조성물에 관한 것이다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (13)
- (a)1종 이상의 충전제와 pH에 독립적인 친수성 중합체로 이루어진 회층; 및 (b)각각 활성 성분을 함유하는 하나 이상의 내층; 으로 이루어지고, 여기서 외층은 투여 후 용해 및 침식의 조합에 의하여 점진적으로 제거되고, 내층 또는 내층들은 용해 및 침식의 조합에 의하여 점진적으로 제거되거나 일단 노출된 후 신속히 붕해되는 것을 특징으로 하는 제약 조성물.
- 제1항에 있어서, 내층 또는 내층들이 일단 노출된 후 신속히 붕해되는 제약 조성물.
- 제1항 또는 제2항에 있어서, 활성 성분을 함유하는 단일 코어층을 갖는 제약 조성물.
- 제1항 내지 3항 중 어느 한 항에 있어서, pH에 독립적인 친수성 중합체 층을 둘러싸고, 활성 성분을 함유하는, 신속히 붕해되는 부가적인 외부 코팅을 갖는 제약 조성물.
- 제1항 내지 4항 중 어느 한 항에 있어서, 활성 성분이 H2-길항제 또는 세로토닌 작용제 또는 길항인 제약 조성물.
- 제5항에 있어서, H2-길항제가 라니티딘 또는 그의 제약학적으로 허용되는 염인 제약 조성물.
- 제5항에 있어서, 세로토닌 작용제가 수마트립탄 또는 그의 제약학적으로 허용되는 염이고, 세로토닌 길항제가 〔1-〔2-〔(메틸술포닐)아미노〕에틸〕-4-피페리디닐〕메틸5-플로오로-2-메톡시-1H-인돌-3-카르복실레이트; 온단세트론; 2,3,4,5-테트라히드로-5-메틸-2-〔(5-메틸-1H-이미다졸-4-일)메틸〕1H-피리돌〔4,3-b〕인돌-1-온; (+)-1,2,3,9-테트라히드로-9-메틸-3-〔(5-메틸-1H-이미다졸-4-일)메틸〕-4H-카르바졸-4-온; 6-플루오로-2,3,4,5-테트라히드로-5-메틸-2-〔(5-메틸-1H-이미다졸-4-일)-메틸〕-1H-피리도〔4,3-b〕인돌-1-온; 또는 그의 제약학적으로 허용되는 염 또는 용매화물인 제약 조성물.
- 제1항 내지 7항 중 어느 한항에 있어서, pH에 독립적인 친수성 중합체가 물중의 2% 농도에서 100cps의 공칭 점도를 갖는 것인 제약 조성물.
- 제1항 내지 8항 중 어느 한 항에 있어서, pH에 독립적인 친수성 중합체가 셀룰로스 에테르, 폴리비닐피롤리돈, 천연 친수성 검의 혼합물, 또는 이들의 혼합물인 제약 조성물.
- 제1항 내지 9항중 어느 한 항에 있어서, 셀룰로스 에테르가 히드록시프로필 메틸셀룰로스인 제약 조성물.
- 제1항 내지 10항 중 어느 한 항에 있어서, 외층이 부가적으로 윤활제 및 활주제를 함유하는 제약 조성물.
- 1종 이상의 충전제와 함께 pH에 독립적인 친수성 중합체로 이루어지는 외층의 혼합물이 각각 활성 성분을 함유하는 하나 이상의 내층의 코어상에 압축 코팅 되는 제1항 내지 제11항 중 어느 한 항에 따른 조성물의 제조방법.
- 제12항에 있어서, 제약 조성물이 추가로 활성 성분을 함유하는 혼합물로 압축 코팅되는 방법.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB919123026A GB9123026D0 (en) | 1991-10-30 | 1991-10-30 | Compositions |
GB919123044A GB9123044D0 (en) | 1991-10-30 | 1991-10-30 | Compositions |
GB9123026.8 | 1992-02-18 | ||
GB9123044.1 | 1992-02-18 | ||
GB929203364A GB9203364D0 (en) | 1992-02-18 | 1992-02-18 | Compositions |
GB9203364.6 | 1992-02-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR930007439A true KR930007439A (ko) | 1993-05-20 |
Family
ID=27265908
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019920020034A KR930007439A (ko) | 1991-10-30 | 1992-10-29 | 방출 조절형 제약 조성물 |
Country Status (21)
Country | Link |
---|---|
US (1) | US5425950A (ko) |
EP (1) | EP0546593B1 (ko) |
JP (1) | JPH05194188A (ko) |
KR (1) | KR930007439A (ko) |
AU (1) | AU666880B2 (ko) |
BE (1) | BE1005490A3 (ko) |
CA (1) | CA2081709C (ko) |
CH (1) | CH685536A5 (ko) |
CZ (1) | CZ325792A3 (ko) |
DE (1) | DE69222006T2 (ko) |
ES (1) | ES2106818T3 (ko) |
FR (1) | FR2683146B1 (ko) |
GB (1) | GB2262445B (ko) |
IE (1) | IE922775A1 (ko) |
IL (1) | IL103593A0 (ko) |
IT (1) | IT1263253B (ko) |
LU (1) | LU88186A1 (ko) |
MX (1) | MX9206236A (ko) |
NO (1) | NO924183L (ko) |
NZ (1) | NZ244921A (ko) |
TW (1) | TW299236B (ko) |
Families Citing this family (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5609884A (en) * | 1992-08-31 | 1997-03-11 | G. D. Searle & Co. | Controlled release naproxen sodium plus naproxen combination tablet |
GB9401894D0 (en) * | 1994-02-01 | 1994-03-30 | Rhone Poulenc Rorer Ltd | New compositions of matter |
JPH07223970A (ja) * | 1994-02-10 | 1995-08-22 | Tanabe Seiyaku Co Ltd | 消化管内適所放出製剤 |
US6887461B1 (en) * | 1998-10-26 | 2005-05-03 | Genetics Institute, Llc | Method of using IL-11 for treating mucositis |
US6548084B2 (en) | 1995-07-20 | 2003-04-15 | Smithkline Beecham Plc | Controlled release compositions |
JPH0940561A (ja) * | 1995-08-02 | 1997-02-10 | Fujitsukusu Kk | 瀉下剤 |
US5837284A (en) * | 1995-12-04 | 1998-11-17 | Mehta; Atul M. | Delivery of multiple doses of medications |
US5922736A (en) * | 1995-12-04 | 1999-07-13 | Celegene Corporation | Chronic, bolus administration of D-threo methylphenidate |
US6486177B2 (en) * | 1995-12-04 | 2002-11-26 | Celgene Corporation | Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate |
US8022095B2 (en) * | 1996-08-16 | 2011-09-20 | Pozen, Inc. | Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs |
GB9706089D0 (en) * | 1997-03-24 | 1997-05-14 | Scherer Ltd R P | Pharmaceutical composition |
US6962997B1 (en) * | 1997-05-22 | 2005-11-08 | Celgene Corporation | Process and intermediates for resolving piperidyl acetamide steroisomers |
IN186245B (ko) | 1997-09-19 | 2001-07-14 | Ranbaxy Lab Ltd | |
US6607751B1 (en) * | 1997-10-10 | 2003-08-19 | Intellipharamaceutics Corp. | Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum |
AU2004222771B2 (en) * | 1998-07-30 | 2006-09-21 | Pfizer Inc. | Prevention of Migraine Recurrence |
GB9816556D0 (en) * | 1998-07-30 | 1998-09-30 | Pfizer Ltd | Therapy |
US6602521B1 (en) * | 1998-09-29 | 2003-08-05 | Impax Pharmaceuticals, Inc. | Multiplex drug delivery system suitable for oral administration |
US20060240105A1 (en) * | 1998-11-02 | 2006-10-26 | Elan Corporation, Plc | Multiparticulate modified release composition |
US20090149479A1 (en) * | 1998-11-02 | 2009-06-11 | Elan Pharma International Limited | Dosing regimen |
IL142896A0 (en) * | 1998-11-02 | 2002-04-21 | Elan Corp Plc | Multiparticulate modified release composition |
US20080118556A1 (en) * | 1998-11-02 | 2008-05-22 | Elan Corporation, Plc | Modified Release of Compositions Containing a Combination of Carbidopa, Levodopa and Entacapone |
PE20001302A1 (es) * | 1998-11-27 | 2000-11-30 | Hoffmann La Roche | Preparaciones de una combinacion farmaceutica que contiene carvedilol e hidroclorotiazida |
US6270807B1 (en) | 1999-03-02 | 2001-08-07 | L. Perrigo Company | Taste-masked pharmaceutical composition |
US6632451B2 (en) * | 1999-06-04 | 2003-10-14 | Dexcel Pharma Technologies Ltd. | Delayed total release two pulse gastrointestinal drug delivery system |
US20040258750A1 (en) * | 1999-06-28 | 2004-12-23 | Gerard Alaux | Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof |
EP1064938A1 (en) * | 1999-06-28 | 2001-01-03 | Sanofi-Synthelabo | Pharmaceutical dosage forms for controlled release producing at least a timed pulse |
US6620431B1 (en) | 2000-04-17 | 2003-09-16 | Charles Signorino | Shellac film coatings providing release at selected pH and method |
US20020028240A1 (en) * | 2000-04-17 | 2002-03-07 | Toyohiro Sawada | Timed-release compression-coated solid composition for oral administration |
IT1318571B1 (it) * | 2000-06-09 | 2003-08-27 | Farmaka Srl | Composizioni cosmetiche per la cura del cuoio capelluto e dei capelli. |
US6500457B1 (en) | 2000-08-14 | 2002-12-31 | Peirce Management, Llc | Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent |
EP1363604A2 (en) * | 2001-02-14 | 2003-11-26 | Glaxo Wellcome S.A. | Pharmaceutical formulation |
AU4061702A (en) * | 2001-05-15 | 2003-04-03 | Mcneil-Ppc, Inc. | Dip coating compositions containing starch or dextrin |
US20030072731A1 (en) * | 2001-05-15 | 2003-04-17 | Cynthia Gulian | Dip coating compositions containing starch or dextrin |
US20030070584A1 (en) * | 2001-05-15 | 2003-04-17 | Cynthia Gulian | Dip coating compositions containing cellulose ethers |
US8309118B2 (en) * | 2001-09-28 | 2012-11-13 | Mcneil-Ppc, Inc. | Film forming compositions containing sucralose |
US20030091630A1 (en) * | 2001-10-25 | 2003-05-15 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data |
US20030104052A1 (en) * | 2001-10-25 | 2003-06-05 | Bret Berner | Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract |
CA2409552A1 (en) * | 2001-10-25 | 2003-04-25 | Depomed, Inc. | Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract |
US20040052843A1 (en) * | 2001-12-24 | 2004-03-18 | Lerner E. Itzhak | Controlled release dosage forms |
EP2172192A1 (en) * | 2001-12-24 | 2010-04-07 | Teva Pharmaceutical Industries Ltd. | Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder of granular material, and process and tooling for producing it |
WO2003086363A1 (en) * | 2002-04-08 | 2003-10-23 | Lavipharm Laboratories Inc. | Drug-complex microparticles and methods of making/using same |
CN1681493A (zh) * | 2002-07-19 | 2005-10-12 | 兰贝克赛实验室有限公司 | 掩味舒马曲坦片剂及其制备方法 |
US7429619B2 (en) * | 2002-08-02 | 2008-09-30 | Mcneil Consumer Healthcare | Polyacrylic film forming compositions |
US20040068000A1 (en) * | 2002-10-02 | 2004-04-08 | Mintong Guo | Compression coated tablets |
US20080220074A1 (en) * | 2002-10-04 | 2008-09-11 | Elan Corporation Plc | Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same |
MY148805A (en) | 2002-10-16 | 2013-05-31 | Takeda Pharmaceutical | Controlled release preparation |
US7332183B2 (en) * | 2002-12-26 | 2008-02-19 | Pozen Inc. | Multilayer dosage forms containing NSAIDs and triptans |
WO2004082679A1 (ja) * | 2003-03-17 | 2004-09-30 | Takeda Pharmaceutical Company Limited | 放出制御組成物 |
US20040241252A1 (en) * | 2003-05-29 | 2004-12-02 | Abney Christopher Charles | Pharmaceutical compositions for oral administration comprising lithium carbonate, processes of making the same, and methods of administering the same |
AU2004247076A1 (en) * | 2003-06-06 | 2004-12-23 | Glaxo Group Limited | Composition comprising triptans and NSAIDs |
US7390503B1 (en) * | 2003-08-22 | 2008-06-24 | Barr Laboratories, Inc. | Ondansetron orally disintegrating tablets |
EP1673073A4 (en) * | 2003-09-29 | 2012-03-21 | Cj Cheiljedang Corp | SLOW RELEASE FORMULATIONS |
GB0400452D0 (en) * | 2004-01-09 | 2004-02-11 | Norton Healthcare Ltd | A pharmaceutical composition |
GB0403628D0 (en) * | 2004-02-18 | 2004-03-24 | Arrow Group Ltd | Compression-coated tablets and the manufacture thereof |
US20050239830A1 (en) * | 2004-04-26 | 2005-10-27 | Vikram Khetani | Methods of diminishing co-abuse potential |
JP2008500288A (ja) * | 2004-05-28 | 2008-01-10 | イメイジノット ピーティーワイ エルティーディー | 経口治療用化合物の供給系 |
US8216610B2 (en) * | 2004-05-28 | 2012-07-10 | Imaginot Pty Ltd. | Oral paracetamol formulations |
US20060024361A1 (en) * | 2004-07-28 | 2006-02-02 | Isa Odidi | Disintegrant assisted controlled release technology |
EP1781262A1 (en) * | 2004-07-29 | 2007-05-09 | Sanofi-Aventis | Pharmaceutical multilayer tablet for controlled_release of active ingredients with highly ph-dependent solubility |
US20060024368A1 (en) * | 2004-07-30 | 2006-02-02 | Reza Fassihi | Compressed composite delivery system for release-rate modulation of bioactives |
US10624858B2 (en) * | 2004-08-23 | 2020-04-21 | Intellipharmaceutics Corp | Controlled release composition using transition coating, and method of preparing same |
EP1793808A1 (en) * | 2004-09-29 | 2007-06-13 | Aurobindo Pharma Limited | Solid unit dosage forms of 5-ht1 agonist |
EP1799264A2 (en) * | 2004-10-08 | 2007-06-27 | Neuromolecular Pharmaceuticals Inc | Methods and compositions for treating migraine pain |
US20060121112A1 (en) * | 2004-12-08 | 2006-06-08 | Elan Corporation, Plc | Topiramate pharmaceutical composition |
CN101076248A (zh) * | 2004-12-09 | 2007-11-21 | 塞尔基因公司 | 使用d-苏型哌甲酯的治疗 |
AU2006235483B2 (en) * | 2005-04-12 | 2010-11-25 | Elan Pharma International Limited | Controlled release compositions comprising a cephalosporin for the treatment of a bacterial infection |
US20100136106A1 (en) * | 2005-06-08 | 2010-06-03 | Gary Liversidge | Modified Release Famciclovir Compositions |
EP3449928A1 (en) * | 2005-11-28 | 2019-03-06 | Imaginot Pty Ltd. | Oral therapeutic compound delivery system |
US10064828B1 (en) | 2005-12-23 | 2018-09-04 | Intellipharmaceutics Corp. | Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems |
MX2008011441A (es) * | 2006-03-06 | 2008-11-18 | Pozen Inc | Formas de dosificacion para administrar combinaciones de farmacos. |
US9265732B2 (en) | 2006-03-06 | 2016-02-23 | Pozen Inc. | Dosage forms for administering combinations of drugs |
JP5349290B2 (ja) * | 2006-04-03 | 2013-11-20 | オディディ,イサ | 薬物送達組成物およびそれを含む医薬品、ならびにその製造方法 |
US9561188B2 (en) | 2006-04-03 | 2017-02-07 | Intellipharmaceutics Corporation | Controlled release delivery device comprising an organosol coat |
US10960077B2 (en) * | 2006-05-12 | 2021-03-30 | Intellipharmaceutics Corp. | Abuse and alcohol resistant drug composition |
ES2400446T5 (es) | 2006-08-03 | 2017-03-13 | Horizon Pharma Ag | Tratamiento con glucocorticoides de liberación retardada de una enfermedad reumática |
EP2813144A1 (en) | 2006-10-09 | 2014-12-17 | Charleston Laboratories, Inc. | Analgesic compositions comprising an antihistamine |
KR100885029B1 (ko) * | 2007-02-07 | 2009-02-23 | 지엘팜텍 주식회사 | 경구투여용 서방성 삼중정제 |
EP1970056A1 (en) * | 2007-03-15 | 2008-09-17 | Polichem S.A. | Time-specific delayed/pulsatile release dosage forms |
US9138430B2 (en) * | 2007-12-27 | 2015-09-22 | Mylan Specialty L.P. | Formulation and method for the release of paroxetine in the large intestine |
ES2620672T3 (es) | 2008-01-09 | 2017-06-29 | Charleston Laboratories, Inc. | Comprimidos de doble capa que comprenden oxicodona y prometazina |
JP2011518881A (ja) * | 2008-04-28 | 2011-06-30 | ゾゲニクス インコーポレーティッド | 片頭痛の治療のための製剤 |
WO2010084188A1 (en) * | 2009-01-26 | 2010-07-29 | Nitec Pharma Ag | Delayed-release glucocorticoid treatment of asthma |
NZ582836A (en) * | 2009-01-30 | 2011-06-30 | Nitec Pharma Ag | Delayed-release glucocorticoid treatment of rheumatoid arthritis by improving signs and symptoms, showing major or complete clinical response and by preventing from joint damage |
EP2403487A2 (en) * | 2009-03-04 | 2012-01-11 | Fdc Limited | Oral controlled release dosage forms for water soluble drugs |
WO2011006012A1 (en) | 2009-07-08 | 2011-01-13 | Charleston Laboratories Inc. | Pharmaceutical compositions |
GB201003731D0 (en) * | 2010-03-05 | 2010-04-21 | Univ Strathclyde | Immediate/delayed drug delivery |
GB201003766D0 (en) | 2010-03-05 | 2010-04-21 | Univ Strathclyde | Pulsatile drug release |
GB201003734D0 (en) | 2010-03-05 | 2010-04-21 | Univ Strathclyde | Delayed prolonged drug delivery |
EA032906B1 (ru) | 2010-12-22 | 2019-08-30 | Пэдью Фарма Л.П. | Твердая лекарственная форма с контролируемым высвобождением и способы ее получения и применения |
KR101458334B1 (ko) | 2010-12-23 | 2014-11-04 | 퍼듀 퍼머 엘피 | 탬퍼 저항성 고체 경구 투여 형태 |
CN105120846B (zh) | 2013-02-05 | 2019-10-18 | 普渡制药公司 | 抗篡改的药物制剂 |
WO2014133008A1 (ja) * | 2013-02-27 | 2014-09-04 | 塩野義製薬株式会社 | Ampk活性化作用を有するインドールおよびアザインドール誘導体 |
US10751287B2 (en) | 2013-03-15 | 2020-08-25 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
KR20170020336A (ko) * | 2014-06-13 | 2017-02-22 | 애버리 데니슨 코포레이션 | 의료용으로 사용되는 개선된 감압 접착제 |
EP3423041A4 (en) | 2016-03-04 | 2019-09-11 | Charleston Laboratories, Inc. | PHARMACEUTICAL COMPOSITIONS |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4892742A (en) * | 1985-11-18 | 1990-01-09 | Hoffmann-La Roche Inc. | Controlled release compositions with zero order release |
DE3720757A1 (de) * | 1987-06-24 | 1989-01-05 | Bayer Ag | Dhp-manteltablette |
DE3814532A1 (de) * | 1988-04-29 | 1989-11-09 | Bayer Ag | Dhp-retard-zubereitung |
US4880636A (en) * | 1988-05-13 | 1989-11-14 | Franz Robert M | Film coated tablet of ranitidine HCl |
US5032406A (en) * | 1989-02-21 | 1991-07-16 | Norwich Eaton Pharmaceuticals, Inc. | Dual-action tablet |
US5085865A (en) * | 1989-04-12 | 1992-02-04 | Warner-Lambert Company | Sustained release pharmaceutical preparations containing an analgesic and a decongestant |
GB9104890D0 (en) * | 1991-03-08 | 1991-04-24 | Glaxo Group Ltd | Compositions |
-
1992
- 1992-10-23 EP EP92203262A patent/EP0546593B1/en not_active Expired - Lifetime
- 1992-10-23 DE DE69222006T patent/DE69222006T2/de not_active Expired - Lifetime
- 1992-10-23 ES ES92203262T patent/ES2106818T3/es not_active Expired - Lifetime
- 1992-10-28 GB GB9222662A patent/GB2262445B/en not_active Expired - Lifetime
- 1992-10-29 JP JP4291571A patent/JPH05194188A/ja active Pending
- 1992-10-29 LU LU88186A patent/LU88186A1/fr unknown
- 1992-10-29 NO NO92924183A patent/NO924183L/no unknown
- 1992-10-29 IL IL103593A patent/IL103593A0/xx unknown
- 1992-10-29 MX MX9206236A patent/MX9206236A/es unknown
- 1992-10-29 BE BE9200937A patent/BE1005490A3/fr not_active IP Right Cessation
- 1992-10-29 FR FR9212932A patent/FR2683146B1/fr not_active Expired - Lifetime
- 1992-10-29 CH CH3390/92A patent/CH685536A5/fr not_active IP Right Cessation
- 1992-10-29 CA CA002081709A patent/CA2081709C/en not_active Expired - Lifetime
- 1992-10-29 CZ CS923257A patent/CZ325792A3/cs unknown
- 1992-10-29 IT ITRM920788A patent/IT1263253B/it active IP Right Grant
- 1992-10-29 TW TW081108615A patent/TW299236B/zh active
- 1992-10-29 KR KR1019920020034A patent/KR930007439A/ko not_active Application Discontinuation
- 1992-10-29 IE IE277592A patent/IE922775A1/en not_active IP Right Cessation
- 1992-10-29 AU AU27469/92A patent/AU666880B2/en not_active Ceased
- 1992-10-29 NZ NZ244921A patent/NZ244921A/en unknown
-
1994
- 1994-05-31 US US08/250,948 patent/US5425950A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
GB2262445A (en) | 1993-06-23 |
DE69222006D1 (de) | 1997-10-09 |
IE922775A1 (en) | 1993-05-05 |
ITRM920788A1 (it) | 1994-04-29 |
CA2081709A1 (en) | 1993-05-01 |
LU88186A1 (fr) | 1993-05-17 |
US5425950A (en) | 1995-06-20 |
EP0546593A1 (en) | 1993-06-16 |
EP0546593B1 (en) | 1997-09-03 |
TW299236B (ko) | 1997-03-01 |
AU666880B2 (en) | 1996-02-29 |
CZ325792A3 (en) | 1993-10-13 |
MX9206236A (es) | 1993-04-01 |
IL103593A0 (en) | 1993-03-15 |
AU2746992A (en) | 1993-05-06 |
ITRM920788A0 (it) | 1992-10-29 |
FR2683146B1 (fr) | 1995-05-12 |
NO924183L (no) | 1993-05-03 |
ES2106818T3 (es) | 1997-11-16 |
NZ244921A (en) | 1995-04-27 |
DE69222006T2 (de) | 1998-01-22 |
CH685536A5 (fr) | 1995-08-15 |
CA2081709C (en) | 2003-09-02 |
BE1005490A3 (fr) | 1993-08-10 |
IT1263253B (it) | 1996-08-05 |
NO924183D0 (no) | 1992-10-29 |
GB2262445B (en) | 1996-05-15 |
FR2683146A1 (fr) | 1993-05-07 |
JPH05194188A (ja) | 1993-08-03 |
GB9222662D0 (en) | 1992-12-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR930007439A (ko) | 방출 조절형 제약 조성물 | |
EE03471B1 (et) | Dopamiini agonisti sisaldav farmatseutiline kompositsioon, selle kasutamine ja valmistamismeetod, farmatseutiline produkt ja komplekt ning antatsiidi kasutamine | |
AU781827B2 (en) | Use of central cannabinoid receptor antagonist for preparing medicines designed to facilitate smoking cessation | |
EP0662322B1 (en) | Pharmaceutical composition for controlled release | |
KR100907640B1 (ko) | 5-ht3 수용체 길항제를 사용한 메트포르민의 구토작용의 억제 | |
EP0106202B1 (en) | Soft capsule | |
HRP20160880T4 (hr) | Formulacija obložene tablete i postupak | |
BG103541A (en) | Pharmaceutical dosed form for quick release and taste masking | |
AU780011B2 (en) | Matrix tablet enabling the prolonged release of trimetazidine after administration by the oral route | |
KR970701544A (ko) | 5-HT_2 길항제를 사용하는 강박반응의 치료법(Treatment of obsessive-compulsive disorders with 5-HT_2 antagonists) | |
DE69432595T2 (de) | Antagonisten des angiotensin ii-rezeptors zur behandlung von chronischen entzündlichen erkrankungen | |
KR880005930A (ko) | 탐닉 치료용 의약품 | |
DE68917738T2 (de) | Therapeutisch aktive substituierte Benzimidazole und Verfahren zu ihrer Herstellung. | |
US20030049319A1 (en) | Once a day antihistamine and decongestant formulation | |
WO1992000103A1 (en) | Pharmaceutical preparations | |
WO1999015202A1 (fr) | Medicaments contre la dysurie resultant d'une hypertrophie de la prostate | |
KR900004340A (ko) | 의약제 | |
KR900004341A (ko) | 의약제 | |
US20020058063A1 (en) | Stable pharmaceutical dosage form for paroxetin anhydrate | |
RU92004573A (ru) | Фармацевтическая композиция с контролируемым выделением и способ ее получения | |
KR20230131299A (ko) | 다중-층 구강용 박막 | |
KR20230131298A (ko) | 다중-층 구강용 박막 | |
AU2003274030B2 (en) | Transmucosal pharmaceutical administration form | |
US20010036474A1 (en) | Endo-N-(9- methyl-9-azabicyclo[3.3.1] non-3-yl)-1-methyl-1H-indazole-3-carboxamide hydrochloride | |
HRP920630A2 (en) | New pharmaceutical preparations having extended delivery |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |